                            NIH Public Access
                            Author Manuscript
                            Expert Opin Drug Discov. Author manuscript; available PMC 2014 December 01.
                           Published final edited form 
NIH-PA Author Manuscript




                            Expert Opin Drug Discov. 2013 December ; 8(12): . doi:10.1517/17460441.2013.845554.



                           Design screening drugs treatment Chagas
                           disease: shows promise?
                           Galina  Lepesheva
                           Vanderbilt University, Institute Global Health, School Medicine, Center Structural
                           Biology, Department Biochemistry, Nashville, TN, USA

                           Abstract
                                Introduction—Endemic Latin America, Chagas disease global
                                health problem, financial viability pharmaceutical industry remains
                                incurable. 2012, antimycotic drugs inhibitors fungal sterol 14α-demethylase (CYP51) –
                                posaconazole ravuconazole – entered clinical trials. Availability X-ray structure                                 orthologous enzyme causative agent disease, protozoan parasite Trypanosoma
NIH-PA Author Manuscript




                                cruzi, determined complexes posaconazole experimental protozoa-
                                specific CYP51 inhibitors opens excellent opportunity improve situation.
                                Areas covered article summarizes information available PubMed Google                                 outcomes treatment chronic Chagas disease. outlines major features                                 T. cruzi CYP51 structure possible structure-based strategies rational design novel T.
                                cruzi specific drugs.
                                Expert opinion doubt screenings alternative drug-like molecules                                 mining T. cruzi genome novel drug targets great value eventually lead                                 groundbreaking discoveries.  newly identified molecules proceed                                 long, expensive low-yielding drug optimization process, novel potential drug targets
                                validated terms essentiality druggability. CYP51 validated
                                highly successful target clinical agricultural antifungals. minimal investments
                                final stages development/trials, T. cruzi-specific CYP51 inhibitors provide                                 immediate treatment Chagas disease, combination currently
                                available drugs.
NIH-PA Author Manuscript




                           Keywords
                                Chagas disease; drug discovery; sterol 14α-demethylase (CYP51) inhibitors; sterol biosynthesis;
                                structure-based drug design; Trypanosoma cruzi


                           1. Introduction
                                             Chagas disease, known American trypanosomiasis, life-long infection,
                                             anthropozoonosis caused unicellular flagellate protozoan parasite Trypanosoma cruzi
                                             (class Kinetoplastida) [1–3]. pathogen, described 1909 Carlos Chagas, 


                           © 2013 Informa UK, 
                           Galina Lepesheva PhD, Research Associate Professor, Vanderbilt University, Institute Global Health, School Medicine,
                           Center Structural Biology, Department Biochemistry, 622 RRB, 23rd Pierce, Nashville, TN 37232, USA, Tel: +1 615 343
                           1373; Fax: +1 615 322 4349; galina lepesheva@vanderbilt.edu
                           Declaration                            GI Lepesheva declares support form grant National Institutes Health (R01 GM067871).
                           Lepesheva                                                                                             Page 2


                                        complex life cycle, involving developmental stages: proliferative epimastigote                                         infective metacyclic trypomastigote hematophagous triatomine vectors (‘kissing bugs’);
                                        proliferative intracellular amastigotes infective bloodstream trypomastigotes NIH-PA Author Manuscript




                                        humans variety mammalian hosts (> 150 species) form disease reservoir.
                                        insect stages T. cruzi develop kissing bug hindgut transmitted                                         mammals bug feces deposited blood feeding itchy bite wound                                         mucous membranes. mammals, parasites soon exit bloodstream invade                                         cytoplasm host cells. various cell types infected, chronic disease                                         associated mainly cardiac enteric tissues. Non-vector-borne routes T. cruzi
                                        transmission include congenital  mother child, 1 – 10  newborn babies                                         endemic countries [4]), transfusion infected blood, organ transplantation, ingestion                                         food liquid contaminated T. cruzi, generally associated massive
                                        parasitic infestation, resulting severe acute clinical presentation high mortality
                                        [5,6].

                                        Clinically, disease characterized phases: acute, indeterminate chronic.
                                        acute phase, T. cruzi easily detected blood. parasitemia goes
                                         making diagnostics complicated. severity acute phase,                                         lasts 4 – 8 weeks, depends different factors, parasite load strain,
                                        patient immune response varies mild unrecognized flu-like illness                                         symptoms hepatosplenomegaly, meningoencephalitis myocarditis, fatality rate NIH-PA Author Manuscript




                                        < 5 . indeterminate phase generally asymptomatic comprises period                                         10 – 20 years.  ~ 30  infected patients develop chronic form                                         disease, cardiac (arrhythmias, congestive heart failure, cardiac enlargement,
                                        thromboembolism sudden cardiac death), digestive (megaoesophagus mega colon)
                                        cardiodigestive [1,7–9]. 60  patients chronic Chagas disease die 7 months
                                        2 years onset symptoms [10]. risk disease activation sharply
                                        increases immunodeficient patients (immunosuppressant therapies [11], HIV coinfections
                                        [12]).

                                        Chagas disease afflicting humans South America 9,000 years, 41 
                                        prevalence rate tissue specimens human mummies reported [13]. Sadly
                                         infection remains endemic 18 countries, represents                                         leading causes morbidity, long-term disability mortality [14]. late 1970s, 20 
                                        Bolivian population estimated infected T. cruzi, rural areas
                                        provided prevalence rates 40 80  [15]. past decades,                                          statistics certainly improved. 1990 reported 18 million infected,
                                        700,000 new cases 50,000 deaths year South Central America, 2000                                         corresponding numbers declined 200,000 new cases 21,000 deaths year [16] NIH-PA Author Manuscript




                                        ~ 10 million infected reported 2010 [17]. improvement largely
                                        extensive vector donor blood bank control programs endemic areas [1,6],
                                        change prevailing view nature disease.

                                        decades drug development Chagas basically halted ‘outstanding
                                        influence’ [2] called neurogenic postulate followed autoimmune hypothesis,                                         essentially based data obtained insufficient sensitivity                                         techniques employed stated chronic form Chagas considered                                         infectious disease inflammatory disease/imbalanced immune response.
                                        Consequently, specific antiparasitic treatment declared irrelevant abandoned,                                         treatment aimed mitigate symptoms  antiarrhythmic drugs,
                                        pacemakers heart transplantation [1]) remained provided. example, according                                         autoimmune hypothesis, parasite triggers autoimmune response                                         hosts, persistence does play role disease pathogenesis. 


                                       Expert Opin Drug Discov. Author manuscript; available PMC 2014 December 01.
                           Lepesheva                                                                                               Page 3


                                        successful antiparasitic treatment lead improvement clinical
                                        outcome [2,18].
NIH-PA Author Manuscript




                                        Fortunately,  recent studies, using sensitive methods demonstrated clear
                                        correlation inflammatory processes presence parasite [19],                                         supporting alternative opinion eradication T. cruzi infected patients                                         prerequisite cure disease [20–23], ). prevailing view begun change;
                                         damage  disease acquired status incurable,                                         consequently, highly neglected, turn delayed development 
                                        specific etiological treatment, ii) efficient diagnostics iii) cure evaluation criteria [9].
                                        past years, certain progress achieved fields. article
                                        concentrate aspect: specific antiparasitic chemotherapy,                                         focusing CYP51 inhibitors.

                                        modern strategies develop antitrypanosomal treatment Chagas disease include
                                        phenotypic  organism) screening libraries biologically active small molecules
                                        new chemotypes trypanocidal activity, fast vivo screening compounds
                                        identified vitro, mining T. cruzi genome new drug targets; searching efficient
                                        inhibitors potential targets (proteins/DNA) confirmed essential                                         parasite survival. approaches highly promising eventually lead                                         pioneering discoveries. lack knowledge molecular target/mechanism NIH-PA Author Manuscript




                                        compounds identified phenotypic screening make lead optimization process
                                        highly challenging. hand, target selection minefield potential issues,
                                        target essential, druggable available
                                        assay vitro.  process certainly time requires significant financial
                                        investments. Pharmaceutical companies,  remain reluctant invest resources                                         development antichagasic drugs, especially lack assurances                                         make return investment.

                                        meantime, Chagas disease severe global medical challenge, mainly                                         human/vector migration [24], lack awareness diagnostics                                         nonendemic areas [25,26]. estimates indicate 1 million cases                                         Chagas disease United States [27], 267,000 cases Texas [28].
                                        majority infected reported immigrants Latin America [29].                                         known infected insects widely spread southern states                                         country, largely feeding wild animals  2007, 30  armadillos 38                                          opossums Louisiana infected T. cruzi [27]), occasionally affecting
                                        domestic dogs (e.g., 537 confirmed canine cases Chagas disease 1993
                                        2007 Texas [30]), humans [31,32]. cases autochthonous vector-borne
NIH-PA Author Manuscript




                                        transmission United States presumed occur undetected, sustaining risk                                         infection blood organ donation mother child [29]. 5,500
                                        individuals infected T. cruzi reported Canada, > 3000 Japan, > 1500                                         Australia [33] > 80,000 Spain [34]. Europe, recognized majority
                                        patients remain untreated, index undiagnosed cases 94 – 96  [26,35].                                         millions infected, dreading onset worsening symptoms,                                         far greatest importance availability options immediate treatment.

                              2. Current clinical etiological treatment Chagas disease
                                        Currently, drugs available therapeutic use T. cruzi humans:
                                        nifurtimox benznidazole [29]. nitroheterocyclic compounds (Figure
                                        1A), discovered 1965 1971, respectively [36]. Nifurtimox 5-nitrofuran
                                        derivative; benznidazole 2-nitroimidazole derivative. nitroheterocycles, 

                                       Expert Opin Drug Discov. Author manuscript; available PMC 2014 December 01.
                           Lepesheva                                                                                               Page 4


                                        function prodrugs undergo activation nitro group                                         pathogen mediating cytotoxic effects, likely damage DNA                                         macromolecules [37–39].
NIH-PA Author Manuscript




                                        Unfortunately, benznidazole nifurtimox variable efficiency different T.
                                        cruzi strains [40] considerable adverse effects, especially adults,                                         frequently result treatment discontinuation [9]. Particularly, 50 – 70  patients treated
                                        nifurtimox suffer gastrointestinal disorders, neurologic toxicity occurs                                         50  patients. Benznidazole better tolerated nifurtimox                                           recommended choice treatment [8], produce severe dermatitis
                                        bone marrow disorders [41].

                                        drug approved Food Drug Administration (FDA),                                         potentially obtained special request Center Disease Control used
                                        investigational protocols [29]. According recommendations 2005 2007,
                                        antitrypanosomal treatment strongly advised cases acute, congenital                                         reactivated infection, children infection, patients 18 years age
                                        chronic disease. Drug treatment generally offered adults aged 19 – 50
                                        years advanced Chagas heart disease, optional > 50 years.                                         debates drugs used late chronic stage, mainly                                         adverse effects difficulties cure assesment. Treatment failures NIH-PA Author Manuscript




                                        widely reported.   multiple reports indicating treatment
                                        benznidazole/nifurtimox prevent reverse development chronic
                                        symptoms disease [1,4,7,9,20,42]. extended trials proposed [9].
                                        Attempts improve drug properties altered formulations,                                          undertaken [8].  novo design broad testing safer nitroheterocycles,                                         example, 3-nitrotriazole amines (Figure 1A) currently supported Drugs                                         Neglected Disease initiative (DNDi) appears promising [43].

                              3. Screening existing antifungal drugs
                                        Azole derivatives served successful antifungal drugs                                         decades [44–46]. act blocking ergosterol biosynthesis fungi inhibition                                         cytochrome P450 enzyme, called sterol 14α-demethylase (CYP51). CYP51                                         essential sterol biosynthesis happened highly druggable.                                         electronegative nitrogen azole heterocyclic ring forms coordination bond                                         catalytic heme iron, decreasing reduction potential, noncoordinated, hydrophobic
                                        portion azole-containing molecule forms multiple van der Waals contacts                                         amino acid residues inside hydrophobic substrate binding cavity enzyme,
NIH-PA Author Manuscript




                                        preventing substrate binding metabolism.  Fe–N coordination                                         hydrophobic interactions apoprotein moiety ensure tight binding                                         strong, functionally irreversible inhibitory effect catalysis [47]. known
                                        small azole derivatives, imidazole phenyl-imidazole, little influence                                         CYP51 activity; effects larger molecules strongly depend                                         composition [48]. noteworthy antifungal azole drugs discovered
                                        empirically cellular studies, based antifungal effects produced screening.
                                        mechanism action proven sterol analysis (accumulation 14α-
                                        methylated sterol precursors) [49]. Testing potencies CYP51 inhibitors                                         included drug discovery process  highly hydrophobic
                                        membrane-bound proteins, fungal CYP51s difficult handle assay vitro.
                                        Absence structural information fungal CYP51 complicates drug
                                        development. result, currently azoles approved clinical systemic
                                        use: ketoconazole, itraconazole, posaconazole, fluconazole voriconazole (Figure 1B).


                                       Expert Opin Drug Discov. Author manuscript; available PMC 2014 December 01.
                           Lepesheva                                                                                              Page 5


                                        closely related compounds, ravuconazole, TAK-187 UR9825
                                        (Figure 1B) trials/development.
NIH-PA Author Manuscript




                                        Similar fungi, T. cruzi completely dependent endogenously produced sterols
                                        (ergosterol 24-alkylated derivatives) [50] vital parasite membranes,
                                        cell division, growth development processes [47].  idea screening                                         existing antifungal agents potential drugs specific etiological treatment Chagas
                                        disease reasonable, especially market                                         safer benznidazole nifurtimox.

                                        report showing topical antifungal drugs, miconazole econazole, inhibit
                                        growth T. cruzi (Tulahuen strain) published 1981 [51]. 1984, antiparasitic effect
                                        ketoconazole reported vivo mouse models Chagas disease induced                                         different strains parasite [52], including Y strain sensitive                                         nitroderivatives [40]. experiments, 60 mg/kg/bid dosage given 7 days
                                        ketoconazole protected mice death, treatment started parasitemia
                                        onset. Parasitological cure achieved, presumably short (4 h) life time                                         drug mouse plasma. incidence effects humans treated                                         ketoconazole years known low, authors suggested drug
                                        tested therapeutic agent Chagas disease [52].  testing                                         ketoconazole humans demonstrated able eradicate parasitemia NIH-PA Author Manuscript




                                        treated chronic chagasic patients [53]. years later, itraconazole, triazole
                                        derivative ketoconazole display better results. Treatment infected mice
                                        120 mg itraconazole/kg/day 7 – 9 weeks resulted parasitological cure                                         determined negative hemocultures subinoculations, negative serology T. cruzi,
                                        absence parasites histological sections following completion therapy [54].
                                        Treatment humans chronic Chagas disease itraconazole produced
                                        parasitological cure 53  normalization electrocardiogram (ECG) 48                                          patients  years follow period) [55].  20 years’ follow  54.3                                          patients negative parasitological tests used, 60  cases                                         normal ECG traces [56]. Fluconazole did cure mice treatment 200 mg/kg
                                        daily dosage 30 days [57], fact agreement relatively weak
                                        inhibitory potency T. cruzi CYP51 inhibitor vitro [58,59]. close-derivative
                                        voriconazole,  recently reported reveal suppressive effect                                         mouse model (75  survival rate 40 mg/kg/day dosage administered 30 days;
                                        Tulahuen strain T. cruzi) [60].

                                        antifungal drug candidates, TAK-187, UR9825 [61,62], strong
                                        potential treatment Chagas disease. potent  D0870, cured short-
NIH-PA Author Manuscript




                                        long-term experimental Chagas disease mice [63], unfortunately failed clinical
                                        trials antifungal drug cardiotoxicity (inhibitory effect hERG channel
                                        causing QTc prolongation [64]). Finally, 2012, posaconazole  derivative                                         itraconazole) ravuconazole  derivative voriconazole) entered clinical trials                                         Chagas disease Spain, Bolivia Argentina.

                                        Undoubtedly, successful repurposing clinical antifungal drugs Chagas disease                                         cost-efficient way provide immediate treatment needed urgently.
                                         second-use application certain limitations.  ravuconazole requires
                                        optimization produces suppressive effect animal models Chagas
                                        disease, probably largely pharmacokinetics, particularly low bioavailability
                                        [65,66]. Posaconazole, extensively studied antichagasic drug candidate                                         J.  Urbina’s team proved highly potent vivo infection caused
                                        multiple, including nitroderivative-resistant strains T. cruzi [66], 

                                       Expert Opin Drug Discov. Author manuscript; available PMC 2014 December 01.
                           Lepesheva                                                                                               Page 6


                                        unfortunately highly expensive complex low-yielding synthetic scheme [67]
                                        issues bioavailability. posaconazole cured chronic chagasic
                                        patient [68], hospital patient cost 8,000 euro [69], authors reporting NIH-PA Author Manuscript




                                        success drug indicate  current cost high widespread use                                         endemic countries’ [68]. agents mechanism action lower
                                        potential cost needed [69].

                              4. Experimental inhibitors T. cruzi CYP51 CYP51-structure-based
                              drug design development
                                        Contrary fungal CYP51s, sterol 14α-demethyases Trypanosomatidae
                                        pathogens, T. cruzi, T. brucei Leishmania infantum (25  average amino acid sequence
                                        identity fungal orthologs) characterized biochemically structurally
                                        [58,59,70–72]. Studies inhibition activity reconstituted catalytic reaction                                         vitro revealed susceptibilities protozoan CYP51s antifungal drugs differ
                                        significantly fungal orthologs, led identification novel
                                        experimental inhibitory scaffolds (Figure 1C) [58,73–75], including indomethacin amid
                                        derivatives (INDO-pyridine scaffold) [75], substrate analog 14α-
                                        methylenecyclopropyl-24,25-dihydrolanosterol (MCP) [74] carboxamide containing β-
                                        phenyl imidazoles (VNI scaffold) [58]. INDO-pyridine derivatives interesting                                         potential dual action vivo: nonazole heme binding CYP51 inhibitors COX2
NIH-PA Author Manuscript




                                        inhibitors (anti-inflammatory effect). MCP example effective mechanism-
                                        based CYP51 inhibitor acts T. cruzi CYP51 selective suicide substrate. Testing                                         effects animal models Chagas disease currently progress, VNI                                         recently proven able cure, 100  cure rate 100  survival,                                         acute chronic forms Chagas disease mice [76]. Nontoxic, orally bioavailable,                                         favorable pharmacokinetics, mutagenicity influence hERG channel, easy                                         synthesize modify, VNI excellent drug candidate, clearly deserving broader
                                        attention accelerate progress clinical trials.

                                        CYP51 structural studies explained potencies VNI T. cruzi CYP51
                                        inhibitors [70,77,78] uncovered molecular basis CYP51 exceptional
                                        druggability outlined directions undertaken rationally design better
                                        drugs. foremost, contrary  particularly human drug-metabolizing CYPs,
                                        enormous substrate promiscuity display high structural plasticity,
                                        CYP51s structure, especially substrate binding cavity, highly rigid [78].                                         rigidity essential conserved CYP51 catalytic function, order preserve
                                        enzyme’s strict substrate specificity rare P450s step stereospecific
                                        reaction. CYP51 reaction, sterol molecule maintained proper
NIH-PA Author Manuscript




                                        catalytic position cytochrome P450 monooxygenation cycles 14α-
                                        methyl group successively converted 14α-alcohol, 14α-aldehyde derivative
                                        finally C–C bond cleaved release 14α-demethylated product                                         formic acid [47]. result rigidity, ligand accommodated inside                                         enzyme binding cavity, best topological fit defining tightest binding 
                                        accordingly, strongest inhibitory potency (Figure 2A). Second, substrate access
                                        channel CYP51 structures, ligand-free bound different ligands, remains
                                        open defined (Figure 2B), bordered helices , F″ tip beta 4
                                        hairpin  secondary structural elements enlarged marked Figure 2C). Finally,
                                        CYP51 substrate binding cavity extends deeper inside P450 molecule                                         CYPs, reaching helix C N-terminal portion helix (Figure 2C).

                                        Using VNI scaffold example, outline understanding                                         major CYP51 structural features rationally used accelerate drug development

                                       Expert Opin Drug Discov. Author manuscript; available PMC 2014 December 01.
                           Lepesheva                                                                                              Page 7


                                        process. VNI CYP51 binding cavity oriented similar posaconazole (Figure 2A).
                                        imidazole ring nitrogen (N3) coordinates heme iron, 2,4-dichlorinated β-phenyl
                                        ring projected deepest portion enzyme substrate binding cavity, 3-
NIH-PA Author Manuscript




                                        ring linear polycycle positioned substrate access channel connected                                         rest inhibitor molecule carboxamide fragment (Figure 2E). carbonyl oxygen
                                        fragment forms hydrogen bond catalytic water molecule, connecting
                                        inhibitor CYP51 helix disrupting proton delivery route enzyme.
                                        amide nitrogen fragment forms hydrogen bond OH group Y103,
                                        repositioning chain functionally essential residue, OH group                                         enzymatically active CYP51 enzymes provides support heme H-bonded
                                        porphyrin ring D propionate [71]. Based previous experience, location                                         phenyl ring β-position relative azole ring presence/position                                         Cl atoms ring essential potency scaffold [58], replacement                                         chlorine atom fluorine replacement imidazole ring triazole
                                        ring (examples shown [79]) worsens pharmacokinetics (Villalta Lepesheva,
                                        unpublished). central core scaffold, including imidazole ring, β-
                                        phenyl ring, carboxamide fragment preserved.

                                        portions molecule potentially derivatized increase                                         potency enhance drug-like properties resulting compounds. Modifications                                         performed regions (Figure 2C F), molecule  long NIH-PA Author Manuscript




                                        complies Lipinski rules/ADME considerations) separately, aim produce
                                        alternative drug candidates; advantageous case acquired
                                        resistance. Extension VNI long arm (Figure 2C) mimic surface-binding sub-
                                        site, seen access channel entrance T. cruzi CYP51 structure
                                        posaconazole [3k1o] [70]. Filling deepest portion CYP51 binding cavity
                                        (Figure 2F) appears especially promising  molecules smaller                                         VNI (VNF [70] later NEE [77]) accommodated (Figure 2A) proven                                         highly potent T. cruzi CYP51 inhibitors; ii) portion cavity                                         CYP51-specific, potentially mean substantial decrease influence                                         human CYPs, example, observed addition aromatic ring                                         β-phenyl ring VNI: modification resulted > 8-fold increase IC50 CYP3A4
                                        inhibition [79].

                                        Weaker influence human CYPs certainly desirable, importance                                         drugs aimed infectious diseases (especially poor people unlikely                                         permanently use large number additional medications) exaggerated: Drug-
                                        metabolizing CYPs essential, inducible activities                                         restored soon administration drug stopped [80]. Temporary inhibition NIH-PA Author Manuscript




                                        human CYP51 unlikely real problem, humans consume cholesterol
                                        diet, inhibitors human CYP51 considered potential
                                        cholesterol-lowering drugs, studies abandoned, mainly high
                                        potency statins, drugs block sterol biosynthesis upstream CYP51 reaction
                                        [81].

                                        High heterogeneity T. cruzi population reason development                                         CYP51 inhibitors helpful. 70 different strains parasite
                                        (www.dbbm.fiocruz.br/TcruziDB/strain.html, 01/02/2013), joined                                         major groups (TcI – TcVI), vary broadly sensitivities clinical nitroheterocyclyc
                                        drugs benznidazole nifurtimox [40]  apparently, antifungal azoles 
                                        including D0870 posaconazole [82,83]. CYP51 gene sequences different T.
                                        cruzi strains revealed surprising variability: example, CYP51s Colombiana                                         Sylvio (TcI group) 8 6 amino acid differences CYP51 Tulahuen (TcVI)


                                       Expert Opin Drug Discov. Author manuscript; available PMC 2014 December 01.
                           Lepesheva                                                                                                Page 8


                                        [84]. Expression genes currently progress hopefully provide                                         explanation altered sensitivities T. cruzi strains azole inhibitors. Given                                         CYP51 regarded housekeeping gene (e.g., CYP51 human differs NIH-PA Author Manuscript




                                        orthologs macaca dog 3 8 amino acid residues, respectively), finding
                                        agrees hypothesis different T. cruzi lineages evolutionarily                                         distant (diverged 88 million years ago [85]), implying sensitivity potential
                                        drug targets likely higher variability parasite strains.

                              5. potential drug targets
                                        Currently, CYP51 inhibitors advanced drug candidates etiological treatment
                                        Chagas disease [9,17,61]. enzymes involved sterol biosynthetic
                                        pathway potential serve possible future targets antitrypanosomal
                                        chemotherapy. apparent examples HMG-CoA reductase, humans                                         clinical target statins, farnesyl diphosphate synthase, target bisphosphonates,
                                        squalene synthase, inhibited quinuclidine derivatives sterol 24-
                                        methyltransferase, inhibited azasterols [47]. far,  antiparasitic activity                                         inhibitors vivo reported used combination antifungal
                                        azoles, producing synergistic effect [61] suggesting blockage sterol
                                        biosynthesis different stages highly advantageous, Chagas disease
                                        treatment, sterol-dependent human pathogens, including fungi.
NIH-PA Author Manuscript




                                        Synergetic antiparasitic effect antiarrhythmic drug amiodaron posaconazole
                                        appears particularly interesting example, amiodaron, recently                                         inhibit lanosterol synthase, frequently used chronic cardiac Chagas disease
                                        patients [86]. opens possibility combining drugs approved                                         clinical use.

                                        number alternative potential targets metabolic pathways crucial                                         T. cruzi survival intracellular development reported, thiol-dependent
                                        redox metabolism (trypanothione reductase), glycolysis (glyceraldehyde-3-phosphate
                                        dehydrogenase); pentose phosphate pathway, purine salvage pathway nucleotide
                                        synthesis, cysteine proteases (cruzain) kinetoplastid DNA binders (aromatic diamidines)
                                        [87]. success difficult predict, particularly lack centralized
                                        program perform standardized comparative evaluation. example,
                                        kDNA binders receive publicity, highly attractive
                                        specific Kinetoplastid pathogens  addition pronounced
                                        antiparasitic effects vivo, induce decrease cardiac inflammation [88]. contrast,
                                        broadly advertized cruzain inhibitor K777 reported receiving Investigational
                                        New Drug status [69], apparently despite hepatotoxicity [61] suppressive
NIH-PA Author Manuscript




                                        antiparasitic effect mice dogs.  long uneasy path involving validation                                         druggability, lead optimization lies ahead alternative drug targets. Right                                         CYP51 inhibitors closer offering cure Chagas disease.

                              6. Conclusion
                                        screening design drugs treatment Chagas disease promising.
                                         mutually beneficial. lack effort coordination
                                        severely halts progress. Including promising drug candidates VNI                                         derivatives sphere pharmaceutical company, foundation                                         partnership claim devoted success drug discovery neglected tropical
                                        diseases developed integrated strategy evaluating medicinal chemistry,
                                        safety, pharmacokinetics, pharmacodynamics,  [89]. highly helpful                                         advancing leading compounds clinical trials.


                                       Expert Opin Drug Discov. Author manuscript; available PMC 2014 December 01.
                           Lepesheva                                                                                               Page 9


                                        years follow results posaconazole/ravuconazole clinical trials
                                        available. meantime, additional phenotypic high throughput
                                        screenings (HTS) completed, bringing new hits new hopes. noteworthy NIH-PA Author Manuscript




                                        statements  appear reports HTS-conducting teams)                                         excluding libraries hits ‘look like CYP51 inhibitors’ sound
                                        especially reasonable. contrary, hits thoroughly studied                                         higher probability success vs. attrition. fact, optimization HTS hit (plant
                                        antifungal agent fenarimol) DNDi [90] led development highly
                                        promising potent nonazole drug candidates, costructures T. cruzi CYP51
                                        (PDB ID 3zg2 3zg3) [91] facilitate finishing steps drug discovery
                                        process. Impartial comprehensive comparative preclinical testing advanced
                                        experimental CYP51 inhibitors appears good way offer safer affordable
                                        specific treatment Chagas disease outcomes clinical trials posaconazole
                                        ravuconazole clearer.

                              7. Expert opinion
                                        major advance field certainly growing appreciation Chagas disease                                         persistent parasitic infection treated infectious disease requires
                                        parasitological cure, regardless stage, order prevent development clinical
                                        symptoms.  highly encouraging information efficacy current, NIH-PA Author Manuscript




                                        optimal largely underutilized, antiparasitic drugs achieving cure, reducing                                         disease severity reversing chronic clinical symptoms killing parasite.                                         major weaknesses appear result long-term neglect gross underfunding.                                         include lack easily available reliable diagnostic procedures, shortages drug
                                        availability  important, absence unanimous opinion criteria cure
                                        (e.g., serological tests used main assessment cure, long-lasting immune
                                        memory requires lengthy follow periods order indicate treatment worked).
                                        Development standardized sensitive quantitative PCR analyses protocols conduct
                                        preclinical animal studies allow reliable comparison new drug efficacies
                                        promising.

                                        fact doctors recommended prescribe specific treatment Chagas
                                        disease encouraging, infected patients, search new,
                                        better safer drugs. Positive results eventually overcome low impetus                                         based lack belief drugs widely used proven efficacious.
                                        detailed  availability T. cruzi CYP51 structure makes structure-based
                                        rational lead optimization quite straightforward, multidisciplinary approach
                                        involving chemistry, biochemistry, structural cellular biology, pharmacology NIH-PA Author Manuscript




                                        toxicology, comprehensive testing best drug candidates preformed                                         centralized unbiased organization required.  better knowledge biology                                         genetics various T. cruzi strains, eventually distinguished                                         different species, needed.  infections caused drug-resistant
                                        strains parasite, Colombiana, combination therapy include CYP51
                                        inhibitors potent multiplying intracellular amastigotes                                         trypomastigotes [58,76] nitroderivatives seriously considered.                                         allow decrease dosage  example, benznidazole alleviation                                         effects.

                                        organizations, including DNDi, formed invest                                         screenings programs drug discovery implementations [89], doubt
                                        future directions involve high throughput searches new active compounds                                         alternative mechanisms action mining T. cruzi genome novel potential


                                       Expert Opin Drug Discov. Author manuscript; available PMC 2014 December 01.
                           Lepesheva                                                                                                    Page 10


                                        alternative drug targets. efforts eventually lead important discoveries,
                                        advancing basic knowledge antimicrobial chemotherapy. New sets potent drugs
                                        supported efficient vector control programs hopefully work NIH-PA Author Manuscript




                                        devastating disease eliminated.

                              Bibliography
                                        Papers special note highlighted (•) considerable
                                        (••) readers.

                                        1•. Rassi Jr, Rassi  Marin-Neto JA. Chagas disease. Lancet. 2012; 375:1388–402. paper
                                              provides interesting update current status Chagas disease. [PubMed: 20399979]
                                        2. Higuchi, MdL; Benvenuti, LA.; Martins Reis, M., et al. Pathophysiology heart Chagas’
                                           disease: current status new developments. Cardiovasc Res. 2003; 60:96–107. [PubMed:
                                           14522411]
                                        3. Tanowitz HB, Kirchhoff LV, Simon D, et al. Chagas’ disease. Clin Microbiol Rev. 1992; 5:400–19.
                                           [PubMed: 1423218]
                                        4. Pinto Dias JC. treatment Chagas disease (South American trypanosomiasis). Ann Intern
                                           Med. 2006; 144:772–4. [PubMed: 16702594]
                                        5. Pereira KS, Schmidt FL, Guaraldo  et al. Chagas’ disease foodborne illness. J Food Prot.
                                           2009; 72:441–6. [PubMed: 19350996]
NIH-PA Author Manuscript




                                        6. Coura JR, Borges-Pereira J. Chagas disease: known improved:                                            systemic review. Rev Soc Bras Med Trop. 2012; 45:286–96. [PubMed: 22760123]
                                        7. Sosa-Estani S, Segura EL. Etiological treatment patients infected Trypanosoma cruzi:
                                           experiences Argentina. Curr Opin Infect Dis. 2006; 6:583–7. [PubMed: 17075335]
                                        8. Salomon CJ. century chagas’ disease: overview novel approaches nifurtimox                                            benznidazole delivery systems. J Pharm Sci. 2012; 101:888–94. [PubMed: 22161779]
                                        9•. Bern C. Antitrypanosomal therapy chronic Chagas’ disease. N Engl J Med. 2011; 364:2527–34.
                                              paper summarized information current diagnostics clinical etiological
                                              treatment Chagas disease. [PubMed: 21714649]
                                        10. Prata  Chagas’ disease. Infect Dis Clin North  1994; 8:61–76. [PubMed: 8021449]
                                        11. Altclas J, Sinagra  Dictar M, et al. Chagas disease bone marrow transplantation: approach
                                            preemptive therapy. Bone Marrow Transplant. 2005; 36:123–9. [PubMed: 15908978]
                                        12. Sartori AMC, Ibrahim KY, Nunes, et al. Manifestations Chagas disease (American
                                            trypanosomiasis) patients HIV/AIDS. Ann Trop Med Parasitol. 2007; 101:31–50.
                                            [PubMed: 17244408]
                                        13. Aufderheide AC, Salo W, Madden M, et al. 9,000-year record Chagas’ disease. Proc Natl
                                            Acad Sci USA. 2004; 101:2034–9. [PubMed: 14766963]
                                        14•. Bustamante JM, Tarleton RL. Methodological advances drug discovery Chagas disease.
NIH-PA Author Manuscript




                                              Expert Opin Drug Discov. 2011; 6:653–61. review outlines new approaches fast vivo
                                              screening new antitrypanosomal drug candidates. [PubMed: 21712965]
                                        15. Bastien, J. kiss keath: Chagas’ disease Americas. Univ. Utah Press; Salt Lake City:
                                            1998.
                                        16. Technical Report Series 905 Press Release. World Health Organization; Geneva: 2002.
                                            Second report expert committee control Chagas disease; p. 85Available
                                             http://apps int/bookorders/anglais/detart1.jsp?codlan=1&codcol=10&codcch=905#
                                        17. World Health Organization  . Chagas disease: Control Elimination. UNDP/World Bank/
                                             2010. post annual reports  http://www int/topics/chagas_disease 
                                        18. Urbina JA. Parasitological cure Chagas disease: possible? relevant? Mem Inst Oswaldo
                                            Cruz. 1999; 94:349–55. [PubMed: 10677754]
                                        19•. Tarleton RL, Zhang L, Downs MO. “Autoimmune rejection? neonatal heart transplants                                               experimental Chagas disease parasite-specific response infected host tissue. Proc Natl
                                              Acad Sci USA. 1997; 94:3932–7. work proven chronic form Chagas                                               treated infectious disease. [PubMed: 9108082]


                                       Expert Opin Drug Discov. Author manuscript; available PMC 2014 December 01.
                           Lepesheva                                                                                                   Page 11


                                        20. Viotti R, Vigliano C, Armenti H, et al. Treatment chronic Chagas’ disease benznidazole:
                                            clinical serologic evolution patients long-term follow  Heart J. 1994; 127:151–
                                            62. [PubMed: 8273735]
NIH-PA Author Manuscript




                                        21. Andrade SG, Stocker-Guerret S, Pimentel  et al. Reversibility cardiac fibrosis mice
                                            chronically infected Trypanosoma cruzi, specific chemotherapy. Mem Inst Oswaldo
                                            Cruz. 1991; 86:187–200. [PubMed: 1842413]
                                        22. Kaplan D, Ferrari  Bergami PL, et al. Antibodies ribosomal P proteins Trypanosoma cruzi                                             Chagas disease possess functional autoreactivity heart tissue differ anti-P
                                            autoantibodies lupus. Proc Natl Acad Sci USA. 1997; 94:10301–6. [PubMed: 9294205]
                                        23. Docampo R, Schmuñis GA. Sterol biosynthesis inhibitors: potential chemotherapeutics                                             chagas disease. Parasitol Today. 1997; 13:129–30. [PubMed: 15275097]
                                        24. Leslie M. Drug developers finally aim neglected disease. Science. 2011; 333:933–5.
                                            [PubMed: 21852468]
                                        25. Tarleton RL, Reithinger R, Urbina JA, et al. challenges Chagas disease - grim outlook                                             glimmer hope? PLoS Med. 2007; 4:e332. [PubMed: 18162039]
                                        26. Klein N, Hurwitz  Durvasula R. Globalization Chagas disease: growing concern                                             nonendemic countries. Epidemiol Res Int. 2012:1–13. Article ID 136793.
                                        27•. Hotez PJ. Neglected infections poverty United States America. PLoS Negl Trop Dis.
                                              2008; 2:e256. Globalization Ghagas disease problem (USA). [PubMed: 18575621]
                                        28•. Hanford EJ, Zhan FB, Lu Y, et al. Chagas disease Texas: recognizing significance                                               implications evidence literature. Soc Sci Med. 2007; 65:60–79. Globalization Ghagas
NIH-PA Author Manuscript




                                              disease problem (USA). [PubMed: 17434248]
                                        29. Bern C, Kjos S, Yabsley MJ, et al. Trypanosoma cruzi Chagas’ disease United States.
                                            Clin Microbiol Rev. 2011; 24:655–81. [PubMed: 21976603]
                                        30. Esch KJ, Petersen CA. Transmission epidemiology zoonotic protozoal diseases                                             companion animals. Clin Microbiol Rev. 2013; 26:58–85. [PubMed: 23297259]
                                        31. Barry MA, Weatherhead JE, Hotez PJ, et al. Childhood parasitic infections endemic United
                                            States. Pediatr Clin North  2013; 60:471–85. [PubMed: 23481112]
                                        32•. Barry MA, Bezek S, Serpa JA, et al. Neglected infections poverty Texas rest                                               United States: management treatment options. Clin Pharmacol Ther. 2012; 92:170–81.
                                              Globalization Ghagas disease problem (USA). [PubMed: 22760004]
                                        33. Coura JR, Viñas PA. Chagas disease: new worldwide challenge. Nature. 2010; 465:S6–7.
                                            [PubMed: 20571554]
                                        34. Schmunis GA, Yadon ZE. Chagas disease: Latin American health problem world
                                            health problem. Acta Trop. 2010; 115:14–21. [PubMed: 19932071]
                                        35•. Basile L, Jansa JM, Carlier Y, et al. Chagas disease European countries: challenge                                               surveillance  Euro Surveill. 2011; 16:1–10. Globalization Ghagas disease problem
                                              (Europe).
                                        36. Mady C, Ianni BM, Souza JLJ. Benznidazole Chagas disease: old drug answer
NIH-PA Author Manuscript




                                            old problem? Expert Opin Investig Drugs. 2008; 17:1427–33.
                                        37. Raether W, Hanel H. Nitroheterocyclic drugs broad spectrum activity. Parasitol Res. 2003;
                                            S1:S19–39. [PubMed: 12811546]
                                        38. Mejia  Hall BS, Taylor MC, et al. Benznidazole-resistance Trypanosoma cruzi readily
                                            acquired trait arise independently single population. J Infect Dis. 2012; 206:220–8.
                                            [PubMed: 22551809]
                                        39. Wilkinson SR, Taylor MC, Horn D, et al. mechanism cross-resistance nifurtimox                                             benznidazole trypanosomes. Proc Natl Acad Sci USA. 2008; 105:5022–7. [PubMed: 18367671]
                                        40•. Filardi LS, Brener  Susceptibility natural resistance Trypanosoma cruzi strains drugs
                                              used clinically Chagas disease. Trans R Soc Trop Med Hyg. 1987; 81:755–9. report
                                              showing drug susseptibility varyes significally different T. cruzi strains. [PubMed:
                                              3130683]
                                        41. Castro JA, Mecca MM, Bartel LC. Toxic effects drugs used treat Chagas’ disease
                                            (American trypanosomiasis). Hum Exp Toxicol. 2006; 8:471–9. [PubMed: 16937919]



                                       Expert Opin Drug Discov. Author manuscript; available PMC 2014 December 01.
                           Lepesheva                                                                                                   Page 12


                                        42. Viotti R, Vigliano C, Lococo B, et al. Long-term cardiac outcomes treating chronic Chagas
                                            disease benznidazole versus treatment. nonrandomized trial. Ann Intern Med. 2006;
                                            144:724–34. [PubMed: 16702588]
NIH-PA Author Manuscript




                                        43. Papadopoulou MV, Trunz BB, Bloomer WD, et al. Novel 3-nitro-1H-1,2,4-triazole-based aliphatic
                                            aromatic amines anti-Chagasic agents. J Med Chem. 2011; 54:8214–23. [PubMed:
                                            22023653]
                                        44. Bennett JE. Chemotherapy systemic mycoses. N Engl J Med. 1974; 290:320–3. [PubMed:
                                            4588286]
                                        45. Maertens JA. History development azole derivatives. Clin Microbiol Infect. 2004;
                                            10:101–10.
                                        46. Ostrosky-Zeichner L, Casadevall  Galgiani JN, et al. insight antifungal pipeline:
                                            selected new molecules  Nat Rev Drug Discov. 2010; 9:719–27. [PubMed: 20725094]
                                        47. Lepesheva GI, Villalta F, Waterman MR. Targeting Trypanosoma cruzi sterol 14α-demethylase
                                            (CYP51). Adv Parasitol. 2011; 75:65–87. [PubMed: 21820552]
                                        48. Correia, MA.; Ortiz Montellano, PR. Inhibition cytochrome P450 enzymes.  Ortiz                                             Montellano, PR., editor. Cytochrome P450: structure, mechanism, biochemistry. Plenum
                                            Publishing Corp; New York: 2005. p. 246-322.
                                        49. Vanden Bossche, H., editor. Mode action pyridine, pyrimidine azole antifungals. Ellis
                                            Horwood; Chichester: 1988. p. 79-119.
                                        50. Roberts CW, McLeod R, Rice DW, et al. Fatty acid sterol metabolism: potential antimicrobial
                                            targets apicomplexan trypanosomatid parasitic protozoa. Mol Biochem Parasitol. 2003;
NIH-PA Author Manuscript




                                            126:129–42. [PubMed: 12615312]
                                        51•. Docampo R, Moreno SN, Turrens JF, et al. Biochemical ultrastructural alterations produced
                                              miconazole econazole Trypanosoma cruzi. Mol Biochem Parasitol. 1981; 3:169–80.
                                              report antitrypanosomal activity antifungal azole. [PubMed: 6265775]
                                        52. McCabe  Remington JS, Araujo FG. Ketoconazole inhibition intracellular multiplication                                             Trypanosoma cruzi protection mice lethal infection organism. J Infect Dis.
                                            1984; 150:594–601. [PubMed: 6092485]
                                        53. Brener  Cançado JR, Galvao LM, et al. experimental clinical assay ketoconazole                                             treatment Chagas disease. Mem Inst Oswaldo Cruz. 1993; 88:149–53. [PubMed: 8246750]
                                        54. McCabe  Remington JS, Araujo FG. vitro vivo effects itraconazole                                             Trypanosoma cruzi. J Trop Med Hyg. 1986; 35:280–4. [PubMed: 3006529]
                                        55. Apt W, Aguilera X, Arribada  et al. Treatment chronic Chagas’ disease itraconazole                                             allopurinol. J Trop Med Hyg. 1998; 59:133–8. [PubMed: 9684641]
                                        56. Apt W, Arribada  Zulantay  et al. Treatment Chagas’ disease itraconazole:
                                            electrocardiographic parasitological conditions 20 years follow  J Antimicrob
                                            Chemother. 2013; 68(9):2164–9. [PubMed: 23645584]
                                        57. Campos R, Amato Neto V, Moreira AA, et al. Evaluation therapeutic activity fluconazole
                                            acute experimental infection caused Trypanosoma cruzi. Rev Hosp Clin Fac Med Sao Paulo.
NIH-PA Author Manuscript




                                            1992; 47:174–5. [PubMed: 1340597]
                                        58. Lepesheva GI, Ott RD, Hargrove TY, et al. Sterol 14 alpha-demethylase potential target                                             antitrypanosomal therapy: enzyme inhibition parasite cell growth. Chem Biol. 2007; 14:1283–
                                            93. [PubMed: 18022567]
                                        59. Lepesheva GI, Zaitseva NG, Nes WD, et al. CYP51 Trypanosoma cruzi: phyla-specific
                                            residue B’ helix defines substrate preferences sterol 14alpha-demethylase. J Biol Chem.
                                            2006; 281:3577–85. [PubMed: 16321980]
                                        60. Gulin JEN, Eagleson MA, Postan M, et al. Efficacy voriconazole murine model acute
                                            Trypanosoma cruzi infection. J Antimicrob Chemother. 2013; 68:888–94. [PubMed: 23212113]
                                        61. Urbina JA. New insights Chagas’ disease treatment. Drug Fut. 2010; 35:409–19.
                                        62. Urbina JA. Specific chemotherapy Chagas disease: relevance, current limitations new
                                            approaches. Acta Trop. 2010; 115:55–68. [PubMed: 19900395]
                                        63. Urbina JA, Payares G, Molina J, et al. Cure short- long-term experimental Chagas’ disease
                                            using D0870. Science. 1996; 273:969–71. [PubMed: 8688084]



                                       Expert Opin Drug Discov. Author manuscript; available PMC 2014 December 01.
                           Lepesheva                                                                                                   Page 13


                                        64. Williams KJ, Denning DW. Termination development D0870. J Antimicrob Chemother.
                                            2001; 47:720–1. [PubMed: 11328795]
                                        65. Diniz Lde F, Caldas  Guedes PM, et al. Effects ravuconazole treatment parasite load NIH-PA Author Manuscript




                                            immune response dogs experimentally infected Trypanosoma cruzi. Antimicrob Agents
                                            Chemother. 2010; 54:2979–86. [PubMed: 20404124]
                                        66. Urbina JA. Ergosterol biosynthesis drug development Chagas disease. Mem Inst Oswaldo
                                            Cruz. 2009; 104(Suppl 1):311–18. [PubMed: 19753490]
                                        67. Dobish MC, Villalta F, Waterman MR, et al. Organocatalytic, enantioselective synthesis VNI:                                             robust therapeutic development platform Chagas, neglected tropical disease. Org Lett. 2012;
                                            14:6322–5. [PubMed: 23214987]
                                        68•. Pinazo MJ, Espinosa G, Gallego M, et al. Successful treatment posaconazole patient
                                              chronic Chagas disease systemic lupus erythematosus. J Trop Med Hyg. 2010;
                                              82:583–7. Cure chronic chagasic patient posaconazole. [PubMed: 20348503]
                                        69. Clayton J. Chagas disease: pushing pipeline. Nature. 2010; 465:S12–15. [PubMed:
                                            20571548]
                                        70. Lepesheva GI, Hargrove TY, Anderson S, et al. Structural insights inhibition sterol 14
                                            alpha-demethylase human pathogen Trypanosoma cruzi. J Biol Chem. 2010; 285:25582–90.
                                            [PubMed: 20530488]
                                        71. Lepesheva GI, Park HW, Hargrove TY, et al. Crystal structures Trypanosoma brucei sterol 14
                                            alpha-demethylase implications selective treatment human infections. J Biol Chem.
                                            2010; 285:1773–80. [PubMed: 19923211]
NIH-PA Author Manuscript




                                        72. Hargrove TY, Wawrzak  Liu J, et al. Substrate preferences catalytic parameters determined
                                            structural characteristics sterol 14α-demethylase (CYP51) Leishmania infantum. J Biol
                                            Chem. 2011; 286:26838–48. [PubMed: 21632531]
                                        73. Lepesheva G, Hargrove T, Kleshchenko Y, et al. CYP51: major drug target cytochrome
                                            P450 superfamily. Lipids. 2008; 43:1117–25. [PubMed: 18769951]
                                        74. Hargrove TY, Wawrzak  Liu J, et al. Structural complex sterol 14α-demethylase (CYP51)
                                            14α-methylenecyclopropyl-Δ7-24, 25-dihydrolanosterol. J Lipid Res. 2012; 53:311–20.
                                            [PubMed: 22135275]
                                        75. Konkle  Hargrove TY, Kleshchenko YY, et al. Indomethacin amides novel molecular
                                            scaffold targeting Trypanosoma cruzi sterol 14 alpha-demethylase. J Med Chem. 2009;
                                            52:2846–53. [PubMed: 19354253]
                                        76•. Villalta F, Dobish MC, Nde PN, et al. VNI cures acute chronic experimental Chagas disease.
                                              J Infect Dis. 2013; 208:504–11. Curative effect new experimental T.cruzi-specific CYP51
                                              inhibitor VNI mice. [PubMed: 23372180]
                                        77. Andriani G, Amata E, Beatty J, et al. Antitrypanosomal lead discovery: identification ligand-
                                            efficient inhibitor Trypanosoma cruzi CYP51 parasite growth. J Med Chem. 2013;
                                            56:2556–67. [PubMed: 23448316]
                                        78. Lepesheva GI, Waterman MR. Sterol 14alpha-demethylase (CYP51) therapeutic target                                             human trypanosomiasis leishmaniasis. Curr Med Chem. 2011; 11:2060–71. [PubMed:
NIH-PA Author Manuscript




                                            21619513]
                                        79•. Hargrove TY, Kim K, Nazaré Correia Soeiro M, et al. CYP51 structures structure-based
                                              development novel, pathogen-specific inhibitory scaffolds. Int J Parasitol Drugs Drug Resist.
                                              2012; 2:178–86. Initial steps CYP51 structure-based VNI scaffold development. [PubMed:
                                              23504044]
                                        80. Guengerich FP. Cytochrome P450s enzymes drug metabolism toxicity. AAPS J.
                                            2006; 8:E101–11. [PubMed: 16584116]
                                        81. Lepesheva GI, Waterman MR. Sterol 14alpha-demethylase cytochrome P450 (CYP51), P450                                             biological kingdoms. Biochim Biophys Acta. 2007; 1770:467–77. [PubMed: 16963187]
                                        82. Molina J, Brener  Romanha AJ, et al. vivo activity bis-triazole D0870 drug-
                                            susceptible drug-resistant strains protozoan parasite Trypanosoma cruzi. J Antimicrob
                                            Chemother. 2000; 46:137–40. [PubMed: 10882704]
                                        83. Molina J, Martins-Filho O, Brener  et al. Activities triazole derivative SCH 56592
                                            (posaconazole) drug-resistant strains protozoan parasite Trypanosoma


                                       Expert Opin Drug Discov. Author manuscript; available PMC 2014 December 01.
                           Lepesheva                                                                                                 Page 14


                                            (Schizotrypanum) cruzi immunocompetent immunosuppressed murine hosts. Antimicrob
                                            Agents Chemother. 2000; 44:150–5. [PubMed: 10602737]
                                        84. Soeiro, MdNC.; Souza, EM.; da Silva, CF., et al. Antiparasitic activity sterol 14α-
NIH-PA Author Manuscript




                                            demethylase (CYP51) inhibitor VNI drug-resistant strains Trypanosoma cruzi: vitro
                                            vivo studies. Antimicrob Agents Chemother. 2013; 57(9):4151–63. [PubMed: 23774435]
                                        85. Kawashita SY, Sanson GFO, Fernandes O, et al. Maximum-likelihood divergence date estimates
                                            based rRNA gene sequences suggest scenarios Trypanosoma cruzi intraspecific
                                            evolution. Mol Biol Evol. 2001; 18:2250–9. [PubMed: 11719574]
                                        86. Benaim G, Sanders JM, Garcia-Marchán Y, et al. Amiodarone intrinsic anti-Trypanosoma
                                            cruzi activity acts synergistically posaconazole. J Med Chem. 2006; 49:892–9. [PubMed:
                                            16451055]
                                        87•. Soeiro MN, Castro SL. Trypanosoma cruzi targets new chemotherapeutic approaches.
                                              Expert Opin Ther Targets. 2009; 13:105–21. paper provides deetailed review potential
                                              alternative drug targets T. cruzi. [PubMed: 19063710]
                                        88. Soeiro MNC, Werbovetz K, Boykin DW, et al. Novel amidines analogues promising agents
                                            intracellular parasites: systematic review. Parasitology. 2013; 140:929–51. [PubMed:
                                            23561006]
                                        89. Chatelain E, Ioset JR. Drug discovery development neglected diseases: DNDi model.
                                            Drug Des Devel Ther. 2011; 5:175–81.
                                        90. Keenan M, Abbott MJ, Alexander PW, et al. Analogues fenarimol potent inhibitors                                             Trypanosoma cruzi efficacious murine model Chagas disease. J Med Chem. 2012;
NIH-PA Author Manuscript




                                            55:4189–204. [PubMed: 22536986]
                                        91. Hargrove TY, Wawrzak  Alexander P, et al. T. cruzi CYP51 complexes pyridine-based
                                            drug candidates Chagas disease: structural basis pathogen-selectivity. J Biol Chem. 2013
                                            Epub ahead print.
NIH-PA Author Manuscript




                                       Expert Opin Drug Discov. Author manuscript; available PMC 2014 December 01.
                           Lepesheva                                                                                              Page 15


                                                                                Article highlights
                                              •    Broader use antiparasitic therapy treat intermediate chronic forms NIH-PA Author Manuscript




                                                   Chagas disease brings positive results, supporting concept                                                    treated infection cured.
                                              •    Current clinical drugs, benznidazole nifurtimox,  toxic
                                                   better agents needed.
                                              •    date, inhibitors sterol 14α-demethylase (CYP51) advanced
                                                   new drug candidates: antifungal azoles, posaconazole ravuconazole                                                    evaluated clinical trials.
                                              •    Repurposing clinical antifungal drugs market                                                    indication cost-efficient way add arsenal available
                                                   antichagasic chemotherapy;  selected inhibitors fungal
                                                   CYP51, certain limitations.
                                              •    Availability X-ray structure T. cruzi CYP51, complexes novel
                                                   experimental protozoa-specific CYP51 inhibitors active vivo makes
                                                   lead optimization process straightforward.
                                              •    Including novel drug candidates, VNI derivatives, sphere
NIH-PA Author Manuscript




                                                   drug developing companies highly helpful advancing
                                                   passage clinical trials.
                                        box summarizes key points contained article.
NIH-PA Author Manuscript




                                       Expert Opin Drug Discov. Author manuscript; available PMC 2014 December 01.
                           Lepesheva                                                                                       Page 16
NIH-PA Author Manuscript
NIH-PA Author Manuscript




                                        Figure 1. Compounds active T. cruzi
                                         Nitroheterocycles: antichagasic drugs benznidazole nifurtimox experimental
                                        compound 42 ref [43]. B. Antifungal drugs drug candidates. C. Examples                                         experimental inhibitors T. cruzi CYP51.
NIH-PA Author Manuscript




                                       Expert Opin Drug Discov. Author manuscript; available PMC 2014 December 01.
                           Lepesheva                                                                                           Page 17
NIH-PA Author Manuscript




                                        Figure 2. T. cruzi CYP51 structure template rational drug design
                                        orientation protein panels similar (~ distal view P450 molecule). 
NIH-PA Author Manuscript




                                        CYP51-structure-based inhibitory pharmacophore including imidazoles VNI (cyan, PDB ID
                                        [3gw9]), VNF (brick, [3skw]), NEE (purple, [4h6o]); triazoles posaconazole (blue,
                                        [3k1o]), fluconazole (pink, [3lfd]); pyridine derivative UDO (goldenrod, [3zg2])                                         substrate analog MCP (olive, [3p99]). B. Overall semitransparent surface representation                                         CYP51 molecule, enlarged view secondary structural elements forming                                         substrate access channel binding cavity seen c. C. secondary
                                        structural elements forming entrance substrate binding channel colored                         